Tricida, Inc. (TCDA) News
Filter TCDA News Items
TCDA News Results
|Loading, please wait...|
TCDA News Highlights
- TCDA's 30 day story count now stands at 2.
- Over the past 4 days, the trend for TCDA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest TCDA News From Around the Web
Below are the latest news stories about TRICIDA INC that investors may wish to consider to help them evaluate TCDA as an investment opportunity.
We're starting off Thursday with an overview of the biggest pre-market stock movers traders will want to keep an eye on!
We're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning!
In the last trading session, 2.95 million Tricida Inc. (NASDAQ:TCDA) shares changed hands as the company’s beta touched 0.19. With the company’s per share price at $0.18 changed hands at $0.01 or 3.16% during last session, the market valuation stood at $10.75M. TCDA’s last price was a discount, traded about -7594.44% off its 52-week high … Tricida Inc. (NASDAQ: TCDA): The Most Interesting Shares Of The Day Read More »
In last trading session, Tricida Inc. (NASDAQ:TCDA) saw 2.22 million shares changing hands with its beta currently measuring 0.17. Company’s recent per share price level of $0.18 trading at $0.0 or -0.33% at ring of the bell on the day assigns it a market valuation of $11.88M. That closing price of TCDA’s stock is at … With 27.78% Distance From Low, Is Tricida Inc. (NASDAQ:TCDA) Still Renewed For Growth? Read More »
In this article, we discuss the 15 most shorted stocks right now. If you want to read about some more shorted stocks, go directly to 5 Most Shorted Stocks Right Now. The stock market has been volatile in the past few months as soaring inflation and rising rates combine to create an uncertain business environment […]
The company earlier this month said it was looking at "strategic alternatives," including a sale in whole or in part.
In a report released today, Serge Belanger from Needham maintained a Hold rating on Tricida (TCDA - Research Report). The company's shares closed yesterday at $0.27.According to TipRanks, Belanger is an analyst with an average return of -4.8% and a 40.40% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Revance Therapeutics, and KalVista Pharmaceuticals.The analyst consensus on Tricida is currently a Moderate Sell rating.See today’s best-performing stocks on TipRanks >>Based on Tricida's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $28.54 million.
SOUTH SAN FRANCISCO, Calif., November 14, 2022--Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives.
The nine-year-old company, which once employed 200 people but now has less than 60, is the third in a triumvirate of kidney drug ventures started by a team led by Gerrit Klaerner.
SOUTH SAN FRANCISCO, Calif., November 02, 2022--Tricida, Inc. (NASDAQ: TCDA), announced today that the Board of Directors has authorized Tricida to initiate a review of strategic alternatives to maximize stakeholder value. To facilitate this review, Tricida has engaged Stifel and its wholly owned affiliate, Miller Buckfire, to serve as investment banking advisors and SierraConstellation Partners LLC to serve as a financial advisor. This strategic review may include consideration of the sale of t